1. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
- Author
-
TURNER, Paul J., ANSOTEGUI, Ignacio J., CAMPBELL, Dianne E., CARDONA, Victoria, EBISAWA, Motohiro, EL-GAMAL, Yehia, FINEMAN, Stanley, GELLER, Mario, GONZALEZ-ESTRADA, Alexei, GREENBERGER, Paul A., LEUNG, Agnes S.Y., LEVIN, Michael E., MURARO, Antonella, BORGES, Mario SÁNCHEZ, SENNA, Gianenrico, TANNO, Luciana K., THONG, Bernard Yu-Hor, Margitta, WORM, Committee, WAO Anaphylaxis, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, The University of Sydney, Hospital Quirónsalud Bizkaia [Bilbao], DataLab Group [Montrouge], Vall d'Hebron University Hospital [Barcelona], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Emory University School of Medicine, Emory University [Atlanta, GA], Academia Nacional de Medicina, Mayo Clinic [Jacksonville], Northwestern University Feinberg School of Medicine, Prince of Wales Hospital, University of Cape Town, Food Allergy Referral Centre Veneto Region [Padua, Italy], Università degli Studi di Padova = University of Padua (Unipd), Centro Médico Docente La Trinidad, Università degli studi di Verona = University of Verona (UNIVR), Hospital Sírio-Libanês [São Paulo, Brazil], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Tan Tock Seng Hospital, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Salvy-Córdoba, Nathalie, Institut Català de la Salut, [Turner PJ] National Heart Lung Institute, Imperial College London, London, UK. Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney, Australia. [Ansotegui IJ] Dept. Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain. [Campbell DE] Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney, Australia. DBV Technologies, Montrouge, France. [Cardona V] Secció d’Al·lèrgia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ebisawa M] Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan. [El-Gamal Y] Pediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Allergy ,Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Anaphylaxis [DISEASES] ,Complex Mixtures::Biological Products::Vaccines::Viral Vaccines [CHEMICALS AND DRUGS] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,0302 clinical medicine ,Pandemic ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,030223 otorhinolaryngology ,Adverse event following immunization ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences ,Anaphylaxis ,COVID-19 (Malaltia) - Vacunació ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,Pulmonary and Respiratory Medicine ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,Polyethylene glycol ,Immunology ,Article ,03 medical and health sciences ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::anafilaxia [ENFERMEDADES] ,medicine ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,Intensive care medicine ,Adverse effect ,business.industry ,Public health ,Medicaments - Efectes secundaris ,COVID-19 ,1103 Clinical Sciences ,medicine.disease ,Anafilaxi ,Coronavirus ,mezclas complejas::productos biológicos::vacunas::vacunas víricas [COMPUESTOS QUÍMICOS Y DROGAS] ,WAO Anaphylaxis Committee ,030228 respiratory system ,Immunization ,Vaccine ,Position paper ,Allergists ,business ,lcsh:RC581-607 - Abstract
Anafilaxi; COVID-19; Polietilenglicol Anafilaxia; COVID-19; Polietilenglicol Anaphylaxis; COVID-19; Polyethylene glycol Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
- Published
- 2021